Merck has opened another front in its campaign to get molnupiravir to market, kicking off a process that could lead to the approval of the oral COVID-19 antiviral in the EU. Things have moved quickly ...

(RTTNews) - Merck & Co., Inc. (MRK) and Ridgeback Biotherapeutics said that the European Medicines Agency or EMA has initiated a rolling review for molnupiravir, an investigational oral antiviral ...

Molnupiravir is the first orally-available antiviral treatment that can be administered directly to people with mild-to-moderate coronavirus disease 2019 (COVID-19). Study: A Randomised -Controlled ...

Merck’s new COVID-19 pill, known as molnupiravir, headed for FDA review for emergency authorization, could potentially carry serious safety issues stemming from the method used to kill the virus, ...

Yesterday I wrote about the potential dangers the antiviral drug molnupiravir could unleash by supercharging new SARS-CoV-2 variants. Today, my focus is on the people who may receive the drug as a ...

After more than one year into the coronavirus disease (COVID-19) pandemic, international vaccination efforts are moving closer to bringing this pandemic to an end. Though several drugs have been ...

KENILWORTH, N.J. & MIAMI--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced that the European Medicines Agency (EMA) ...

Weighing three outpatient treatments for COVID-19, the drug cost watchdog Institute for Clinical and Economic Review (ICER) has determined that Pfizer’s Paxlovid, Merck and Ridgeback Biotherapeutics’ ...

One day after authorizing Pfizer's COVID-19 treatment pills, the US Food and Drug Administration on Thursday cleared a second pill -- this one from Merck -- for treating the virus under the agency's ...

Advisers to the US Food and Drug Administration voted 13-10 Tuesday to recommend emergency use authorization of a pill made by Merck and Ridgeback Biotherapeutics to help treat Covid-19. Members of ...